1-20 of 80
Peter A. Riedell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma

Laura Samples, Hossein Sadrzadeh, Matthew J. Frigault, Caron A. Jacobson, Mehdi Hamadani, Ashwath Gurumurthi, Paolo Strati, Roni Shouval, Ariela Noy, Peter A Riedell, Saurabh Dahiya, David G Maloney, Brian G Till, Alexandre V. Hirayama, Jordan Gauthier, Ajay K Gopal, Stephen D Smith, Christina Poh, Ryan C Lynch, Chaitra Ujjani, Mengyang Di, Vikram Raghunathan, Mehrdad Shakib-Azar, Kikkeri N Naresh, Ted A Gooley, Jean A. Yared, Michael D Jain, Frederick L Locke, Lori A. Leslie, Narendranath Epperla, Monalisa Ghosh, Alan P Skarbnik, Brian T. Hill, Manali Kamdar, Valentín Ortiz-Maldonado, Nuria Martínez-Cibrian, Leyla Shune, Mazyar Shadman
Journal: Blood
Blood blood.2024026831.
https://doi.org/10.1182/blood.2024026831
Published: 2025
Includes: Supplemental data
Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)

Clinical Trials & Observations
Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wullf, Chad M. Williams, Joshua Winters, Ioana Magdalena Kloos, Dr, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood blood.2024027347.
https://doi.org/10.1182/blood.2024027347
Published: 2025
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Tanya Siddiqi, Jordan Gauthier, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Charalambos Andreadis, Daniel A. Ermann, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 4633.
https://doi.org/10.1182/blood-2024-200840
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Journal: Blood
Blood (2024) 144 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2024-198056
Published: 2024
Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Peter A. Riedell, Mi Kwon, Ian W. Flinn, Michael J. Dickinson, Carlos Solano, Ulrich Jaeger, Javier Briones, Koji Kato, Shaun Fleming, Emmanuel Bachy, Alessandro Rambaldi, Leyla O. Shune, Nirav N. Shah, Didier Blaise, Matthew J. Frigault, Aravind Ramakrishnan, Anne Yang, David Pearson, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
Journal: Blood
Blood (2024) 144 (Supplement 1): 67.
https://doi.org/10.1182/blood-2024-204264
Published: 2024
Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Matthew Hamby, Brian Egleston, Zachary AK Frosch, Raphael E. Steiner, Ariela Noy, Veronica Carvajal, Seda S. Tolu, Gaston Jean-Louis, Jennifer E. Amengual, Romil Patel, Sairah Ahmed, Timothy Voorhees, Robert Baiocchi, Andres Ramirez-Gamero, Jorge J. Castillo, Emily Hamburger, Christopher Dittus, Imran A. Nizamuddin, Neha Mehta-Shah, Nyein Nyein Thaw Dar, Jose Sandoval-Sus, Alexandra E. Rojek, Peter A. Riedell, Vinod Solipuram, Paul G. Rubinstein, Anthony Ariotti, Gita Suneja, Alexander Vartanov, Charles Milrod, Adam J. Olszewski, Gordon Smilnak, Emily Ayers, Sahaj Desai, Joanna M. Rhodes, Gabriella Magarelli, Tatyana Feldman, Meredith Pellon, David M. Aboulafia, William Bae, Carlos Galvez, Vineel Bhatlapenumarthi, Mehdi Hamadani, Stefan K. Barta
Journal: Blood
Blood (2024) 144 (Supplement 1): 573.
https://doi.org/10.1182/blood-2024-198008
Published: 2024
Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 987.
https://doi.org/10.1182/blood-2024-198452
Published: 2024
Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Zachary D. Epstein-Peterson, Anath C. Lionel, Ashlee Joseph, Esther Drill, Suheil Albert Atallah-Yunes, Taylor R. Brooks, Elise A. Chong, Emeline R. Chong, Jamie Dela Cruz, Matthew J. Frank, Andrew Ip, Madiha Iqbal, Caron A. Jacobson, Manali K. Kamdar, Reem Karmali, Kami J. Maddocks, Matthew Matasar, Reid W. Merryman, Javier Munoz, Peter A. Riedell, Christine E. Ryan, Gilles Salles, Craig S. Sauter, Yazeed Sawalha, Roni Shouval, Navika Shukla, Alexander V. Stanisic, Dylan Therwhanger, Herman Van Besien, Yucai Wang, Samuel Yamshon, Andrew D. Zelenetz, Maria Lia Palomba, Preetesh Jain, Anita Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 238.
https://doi.org/10.1182/blood-2024-192995
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps, Peter A. Riedell, Herbert A. Eradat, Saad S. Kenderian, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Scott R. Solomon, Daniel A. Ermann, Jon E. Arnason, Abhinav Deol, Tatyana Feldman, Charalambos Andreadis, Monalisa Ghosh, Shuo Ma, Stephen J. Schuster, Usama Gergis, Julie M. Vose, Jacob D. Soumerai, Koen van Besien, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 887.
https://doi.org/10.1182/blood-2024-200339
Published: 2024
Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Catherine Thieblemont, Martin Dreyling, Michael J. Dickinson, Joaquín Martínez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose Antonio Pérez-Simón, Andy Chen, Loretta Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E.M. Patten, Joseph P. McGuirk, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Davide Germano, Roberto Javier Ramos, Pei Hsu, Stephen J. Schuster, Nathan H. Fowler
Journal: Blood
Blood (2024) 144 (Supplement 1): 3034.
https://doi.org/10.1182/blood-2024-201730
Published: 2024
Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef
Journal: Blood
Blood (2024) 144 (Supplement 1): 7614.
https://doi.org/10.1182/blood-2024-207898
Published: 2024
Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg
Journal: Blood
Blood (2024) 144 (Supplement 1): 4503.
https://doi.org/10.1182/blood-2024-198153
Published: 2024
Journal Articles

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Peter A. Riedell, Krish Patel, Vanessa Dunleavy, Yasmin H. Karimi, Nirav N. Shah, Vincent Ribrag, Loic Ysebaert, Robin Noel, Gabriel Brisou, Justin Kline, Chet Bohac, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nancy Chen, Jean-Marie Michot, Benoîtt Tessoulin, Sairah Ahmed
Journal: Blood
Blood (2024) 144 (Supplement 1): 4497.
https://doi.org/10.1182/blood-2024-203668
Published: 2024
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Inhibition of PI3Kγ/δ Signaling Promotes an Early Memory State in CAR T Cells and Enhances Their In Vivo Persistence and Efficacy

Alexandra E. Rojek, Lishi Xie, Alan J. Cooper, Xiufen Chen, Peter A. Riedell, Michael R Bishop, Justin Kline
Journal: Blood
Blood (2024) 144 (Supplement 1): 2026.
https://doi.org/10.1182/blood-2024-198199
Published: 2024
Journal Articles

BsAbs before CD19 CAR-T: full speed ahead!

Peter A. Riedell
Journal: Blood
Blood (2024) 144 (3): 249–251.
https://doi.org/10.1182/blood.2024025048
Published: 2024
Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Clinical Trials & Observations
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez-Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thieblemont, Stephen J. Schuster
Journal: Blood
Blood (2024) 143 (17): 1713–1725.
https://doi.org/10.1182/blood.2023021567
Published: 2024
Includes: Supplemental data
Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Alison R Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Journal: Blood
Blood (2023) 142 (Supplement 1): 105.
https://doi.org/10.1182/blood-2023-180952
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood
Blood (2023) 142 (Supplement 1): 617.
https://doi.org/10.1182/blood-2023-184862
Published: 2023